Nearly a decade of Drugs to Watch

Review the history of drugs identified as potential blockbusters

Download Drugs to Watch 2021

Annually since January 2013, the Clarivate expert team has analyzed and selected the Drugs to Watch. While the underlying process has remained the same, the technologies have evolved, and new tools, such as Drug Timelines & Success Rates, are now available to inform the analysis.

Learn more about our methods

Drug Name Company Therapy Area Year
Aducanumab Biogen Inc, Esai Co Ltd Neurology/psychiatric - Alzheimer’s disease 2021
Alirocumab (Praluent) Regeneron Pharmaceuticals Inc., Sanofi SA Cardiovascular disease 2015
Apalutamide (Erleada) Johnson & Johnson Oncology 2018
Apremilast (Otezla) Celgene Corporation Excessive immune response/autoimmunity 2013
Avelumab (Bavencio) Merck Serono, Pfizer Inc. Oncology 2017
Axicabtagene ciloleucel (KTE-C19; Yescarta) Kite Pharma Oncology 2017
Baricitinib (Olumiant) Eli Lilly and Co., Incyte Corp. Excessive immune response/autoimmunity 2017
Betibeglogene darolentivec (LentiGlobin) bluebird bio Inc. Genetic disorder 2019
Bimekizumab UCB Excessive immune response/autoimmunity - psoriasis 2021
Brexpiprazole (Rexulti) Lundbeck, Otsuka Pharmaceutical Neurology/psychiatric 2015
Buprenorphine (Sublocade) Indivior plc Addiction 2018
Cannabidiol (Epidiolex) GW Pharmaceuticals plc Neurology/psychiatric 2018
Dupilumab (Dupixent) Regeneron Pharmaceuticals Inc., Sanofi SA Excessive immune response/autoimmunity 2017
Durvalumab (Imfinzi) AstraZeneca plc Oncology 2017
Elagolix (Orilissa) AbbVie Inc. Reproductive health 2018
Emicizumab (Hemlibra) Chugai, Roche Hematology 2018
Emtricitabine plus tenofovir alafenamide (Descovy) Gilead Sciences Inc., Japan Tobacco Infectious disease 2016
Erenumab (Aimovig) Amgen, Novartis International AG Neurology/psychiatric 2018

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team